drugset
drugset / Press release

Phase 1 Data for Flotetuzumab, MacroGenics' CD123 x CD3 DART® Molecule, Accepted for Oral Presentation at ESMO Congress 2017

2017-07-17 · MacroGenics · original macrogenics.com ↗

Flotetuzumab

Phase 1 Data for Flotetuzumab, MacroGenics' CD123 x CD3 DART® Molecule, Accepted for Oral Presentation at ESMO Congress 2017 14 KB

The release as fetched from its publisher. macrogenics.com ↗